Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

So, the supplements are particularly useful for individuals whose atrophy does not yet fully involve ... and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

A lawsuit alleges that I Love Sugar’s website violates the Americans with Disabilities Act by being inaccessible to blind ...

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...

Yemeni woman travels to UAE for life-changing treatment, reinforcing Abu Dhabi’s status as a global healthcare hub ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Routine evaluation of meibomian glands, starting in childhood, is crucial for identifying and managing this progressive disease before it leads to long-term ocular surface issues.

IZERVAY dosing approved beyond 12 monthsTOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Ok ...